150 related articles for article (PubMed ID: 38644588)
1. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L
Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
de Groof EJ; Stevens TW; Eshuis EJ; Gardenbroek TJ; Bosmans JE; van Dongen JM; Mol B; Buskens CJ; Stokkers PCF; Hart A; D'Haens GR; Bemelman WA; Ponsioen CY;
Gut; 2019 Oct; 68(10):1774-1780. PubMed ID: 31233395
[TBL] [Abstract][Full Text] [Related]
9. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.
Catt H; Bodger K; Kirkham JJ; Hughes DA
Pharmacoeconomics; 2019 Dec; 37(12):1509-1523. PubMed ID: 31372948
[TBL] [Abstract][Full Text] [Related]
10. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.
Vasudevan A; Ip F; Liew D; van Langenberg DR
Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in paediatric inflammatory bowel disease.
Sieczkowska-Golub J; Jarzebicka D; Oracz G; Kierkus J
World J Gastroenterol; 2018 Sep; 24(35):4021-4027. PubMed ID: 30254406
[TBL] [Abstract][Full Text] [Related]
12. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
Jongsma MME; Vuijk SA; Cozijnsen MA; van Pieterson M; Norbruis OF; Groeneweg M; Wolters VM; van Wering HM; Hojsak I; Kolho KL; van Wijk MP; Teklenburg-Roord STA; de Meij TGJ; Escher JC; de Ridder L
Eur J Pediatr; 2022 Aug; 181(8):3055-3065. PubMed ID: 35672586
[TBL] [Abstract][Full Text] [Related]
14. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
D'Haens G; Baert F; van Assche G; Caenepeel P; Vergauwe P; Tuynman H; De Vos M; van Deventer S; Stitt L; Donner A; Vermeire S; Van De Mierop FJ; Coche JR; van der Woude J; Ochsenkühn T; van Bodegraven AA; Van Hootegem PP; Lambrecht GL; Mana F; Rutgeerts P; Feagan BG; Hommes D; ;
Lancet; 2008 Feb; 371(9613):660-667. PubMed ID: 18295023
[TBL] [Abstract][Full Text] [Related]
15. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Chande N; Patton PH; Tsoulis DJ; Thomas BS; MacDonald JK
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD000067. PubMed ID: 26517527
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Wang Y; Tsoulis DJ; MacDonald JK; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD003459. PubMed ID: 25099640
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
